CSBio CSBio

X
[{"orgOrder":0,"company":"Biorchestra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIORCHESTRA, Presenting Lead Candidate BMD-001 for Alzheimer's disease and Drug Delivery System Technology at the 2022 BIO International Convention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biorchestra"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$861.0 million","upfrontCash":"Undisclosed","newsHeadline":"BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Biorchestra"},{"orgOrder":0,"company":"ANL Bio","sponsor":"Biovian","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANLBIO Selected Biovian for Manufacturing of AAV-based product for The Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"ANL Bio"},{"orgOrder":0,"company":"Neuramedy","sponsor":"Bioasis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioasis and Neuramedy Enter into Research Collaboration and License Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Neuramedy"},{"orgOrder":0,"company":"Genuv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Genuv"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,060.0 million","upfrontCash":"$75.0 million","newsHeadline":"ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"ABL Bio"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Global Biopharmaceutical will Leverage Biorchestra Targeting Technology Platform, BDDS™ to Develop Nucleic Acid Therapies, including BMD-001, for Treatment of Neurological Disorders in Multiple Targets.

            Lead Product(s): BMD-001

            Therapeutic Area: Neurology Product Name: BMD-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $861.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BMD-001 (or BDDS : miR-485-3p ASO) is an antisense oligonucleotides encapsulated with proprietary Brin polymer to cross blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation and neurodegeneration.

            Lead Product(s): BMD-001

            Therapeutic Area: Neurology Product Name: BMD-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 09, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SNR1611 is drug candidate that has been repurposed for neurodegenerative disease from a previously FDA-approved anti-cancer drug, has already confirmed SNR1611’s effect on neuron regeneration and functional recovery through preclinical research.

            Lead Product(s): SNR1611

            Therapeutic Area: Neurology Product Name: SNR1611

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.

            Lead Product(s): Tomaralimab

            Therapeutic Area: Neurology Product Name: NM-101

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bioasis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement covers process development for ANLBIO’s gene therapy vector, ANL-101, followed by 200 L scale production. The manufacturing part of the agreement covers upscaling of the process to working volume of 100s of liters and subsequent manufacture facilities.

            Lead Product(s): ANL-101

            Therapeutic Area: Neurology Product Name: ANL-101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Biovian

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.

            Lead Product(s): ABL301

            Therapeutic Area: Neurology Product Name: ABL301

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $1,060.0 million Upfront Cash: $75.0 million

            Deal Type: Collaboration January 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY